

(BMSIC/DRUGS/15-05)

S.N.	Technical Eligibility Criteria as per NIT	Name of Bidder :Unison Pharmaceuticals Address:Plot no.-124,EPIP,Phase-1, JharMajri,Baddi,Distt-solon(HP)174103 "Chart has been prepared on the basis of number of downloaded Pg. received (i.e.- 1-138) "
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	Copy of Partnership Deed between Sri Vijay Kumar and Sri Anand Uppal with registration under Indian partnership act-1932 in Form-C vide letter no 170 of 2008 dt 26.12.2008 submitted.(Pg No-102-106) Bidder details-Name, Addresss, Telephone No, E-Mail and Fax No of Parterns of the company as per annexure V submitted..(Pg No-107)
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As	Self Attested copy of Power of Attorney given by one Partner Mr Anand Uppal with the name of Mr. Prem Nath General Manager as Authorised signatory to file the Tender submitted.(Pg No-33-34)
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)	List of quoted item (Products NIT S.No-9. Amikacin Inj. IP 100mg/2ml , 10. Amikacin Inj. IP 250mg/2ml , 16. Amoxycillin Capsules IP 500mg , 17. Amoxycillin Capsules IP 250mg, 21. Ampicillin & Cloxacillin Inj. , 36. Calcium tablets, 42. Cefixime Tablets IP 50mg, 44. Cefixime Tablets IP 100mg, 46. Cefotaxime Sodium Inj. IP 1gm, 47. Cefotaxime Sodium Inj. IP 250mg, 48 Cefotaxime Sodium Inj. IP 500mg, 50 Ceftazidime Inj. IP 500mg, 51 Ceftazidime Inj. Ip 250mg, 52 Ceftazidime Inj. Ip 1g, 53 Ceftriaxone & Salbactum For Inj. , 54 Ceftriaxone & Salbactum for Inj., 55 Ceftriaxone Inj. 250mg , 56 Ceftriaxone Inj. IP 500mg, 57 Cefuroxime Axetil Ip 125mg, 62 Chlorpheniramine Inj. IP 10mg/ml, 64 Ciprofloxacin Eye Drops Ip 0.3% w/v, 67 Clindamycin Inj. IP 150mg/ ml, 75 Dexamethasone Inj. IP 4mg/ml, 76 Dexamethasone Inj. IP 4mg/ml, 97 Gentamicin Eye Drops IP 0.3% w/v of Gentamicin, 98 Gentamicin Inj. IP 40mg/ml, 105 Hydrocortisone Sodium Succinate Inj. IP 100mg, 128 Meropenem Inj. IP 500mg, 129 Meropenem Inj. IP 1000mg, 130 Metaclopramide Inj. IP 5mg/ml, 143 Moxifloxacin Eye Drops 0.5% w/v, 150 Ofloxacin Ophthalmic Solution IP 0.3% w/v, 157 Pantoprazole for Inj. 40mg, 165 Piperacillin & Tazobactum for Inj. 176 Rabeprazole sodium for Inj. 20mg. (Total items 35)(ref. pg. no. 42-47)
4	<ul style="list-style-type: none">• Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f).• Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f).• Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f). Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)	Copy Of Manufacturing Licence in Form-25 & 28 having Mfg no. MNB/08/713 and MB/08/714 issued on 30.07.2008 & valid upto 29.07.2013 Submitted. (Pg. no. 99-100) Renewal in Form -26 having Mfg no.MNB/08/713 and MB/08/714 issued on 30.07.2008 ,renewed up to 29.07.2018. Submitted. (Pg No-97) Approved products list:- NIT S.No-9 Amikacin Inj. IP 100mg/2ml (Approved on dtd. 30.07.2008 Pg. no. 96, sl.no. 117), 10. Amikacin Inj. IP 250mg/2ml (Approved on dtd. 30.07.2008 Pg. no. 95, sl.no. 119), 16. Amoxycillin Capsules IP 500mg (Approved on dtd. 05.06.2011 Pg. no. 94, sl.no. 23), 17. Amoxycillin Capsules IP 250mg (Approved on dtd.05.06.2011 Pg. no. 94, sl.no. 24), 21. Ampicillin & Cloxacillin Inj. (Approved on dtd. 30.07.2008 Pg. no. 90, sl.no. 53) , 36. Calcium tablets (Approved on dtd. 20.05.2011 Pg. no. 89, sl.no. 25, In which composition column it is written that Each film coated tablet contains Calcium Carbonate IP 1250mg Eq. to elemental calcium 500mg), 42. Cefixime Tablets IP 50mg (Approved on dtd. 29.03.2010 Pg. no. 87, sl.no. 6), 44. Cefixime Tablets IP 100mg (Approved on dtd. 05.06.2012 Pg. no. 85, sl.no. 5), 46. Cefotaxime Sodium Inj. IP 1gm (Approved on dtd. 30.07.2008 Pg. no. 83, sl.no. 104), 47. Cefotaxime Sodium Inj. IP 250mg (Approved on dtd. 30.07.2008 Pg. no. 82, sl.no. 102), 48. Cefotaxime Sodium Inj. IP 500mg (Approved on dtd. 30.07.2008 Pg. no. 81, sl.no. 103), 50. Ceftazidime Inj. IP 500mg (Approved on dtd. 30.07.2008 Pg. no. 80, sl.no. 90), 51. Ceftazidime Inj. IP 250mg (Approved on dtd. 30.07.2008 Pg. no. 79, sl.no. 72), 52. Ceftazidime Inj. Ip 1g (Approved on dtd. 30.07.2006 Pg. no. 78, sl.no. 74), 53. Ceftriaxone & Salbactum For Inj. (Approved on dtd. 01.07.2010 Pg. no. 77, sl.no. 28) , 54. Ceftriaxone & Salbactum for Inj. (Approved on dtd. 31.07.2013 Pg. no. 75, sl.no. 5, in which 3 years not complies as per clause 3(f) , 55. Ceftriaxone Inj. 250mg (Approved on dtd. 30.07.2008 Pg. no. 74, sl.no. 1) , 56. Ceftriaxone Inj. IP 500mg (Approved on dtd. 30.07.2008 Pg. no. 72, sl. no. 2), 57. Cefuroxime Axetil IP 125mg (Approved on dtd. 29.03.2010 Pg. no. 70, sl.no. 106), 62. Chlorpheniramine Inj. IP 10mg/ml (Approved on dtd. 30.07.2008 Pg. no. 69, sl.no. 145), 64. Ciprofloxacin Eye Drops IP 0.3% w/v (Approved on dtd. 30.07.2008 Pg. no. 68, sl.no. 3), 67. Clindamycin Inj. IP 150mg/ml (Approved on dtd. 10.01.2012 Pg. no. 66, sl.no. 116), in which Composition column it is written that Clindamycin phosphate USP Eq. to clindamycin 150mg which is not as per NIT specification, 75. Dexamethasone Inj. IP 4mg/ml, (Approved on dtd. 30.07.2008 Pg. no. 65, sl. no. 132, pack size not mentioned, NIT specification is 2ml vial), 76. Dexamethasone Inj. IP 4mg/ml (The same approval of NIT sl.no. 75 is submitted) (Approved on dtd. 30.07.2008 Refer pg. no. 65, pack size not mentioned, NIT specification is 10ml vial), 97. Gentamicin Eye Drops IP 0.3% w/v of Gentamicin (Approved on dtd. 30.07.2008 Pg. no. 64, sl.no. 2), 98. Gentamicin Inj. IP 40mg/ml (Approved on dtd. 30.07.2008 Pg. no. 62, sl.no. 133 pack size not mentioned, NIT specification is 2ml vial), 105. Hydrocortisone Sodium Succinate Inj. IP 100mg (Approved on dtd. 21.05.2012 Pg. no. 61, sl.no. not clear), in which product composition is in USP which is not as per NIT specification , 128. Meropenem Inj. IP 500mg (Approved on dtd. 29.03.2010 Pg. no. 59, sl.no. 82), 129. Meropenem Inj. IP 1000mg (Approved on dtd. 25.02.2010 Pg. no. 58, sl.no. 71), 130. Metaclopramide Inj. IP 5mg/ml (Approved on dtd. 30.07.2008 Pg. no. Pg. no. 57, sl.no. 148, pack size not mentioned, NIT specification is 2ml vial), 143. Moxifloxacin Eye Drops 0.5% w/v (Approved on dtd. 22.10.2008 Pg. no. 56, sl.no. 25, in which product composition not as per NIT specification & pack size not mentioned, NIT specification is 5ml pack), 150. Ofloxacin Ophthalmic Solution IP 0.3% w/v (Approved on dtd. 30.07.2008 Pg. no. 55), 157. Pantoprazole for Inj. 40mg (Approved on dtd. 05.06.2012 Pg. no. 53), 165. Piperacillin & Tazobactum for Inj. (Approved on dtd. 31.12.2010 Pg. no. 51, sl.no. 75), 176. Rabeprazole sodium for Inj. 20mg (Approved on dtd. 28.06.2011 Pg. no. 50, sl.no.26). (Total items 35)
5	In case of Importer, the bidder (Importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.As per Clause 3(g)	NA

6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	Self attested copies of Market standing certificates for last three year for quoted product issued by the State Drug controller & Licensing Authority Baddi, Solan. vide letter no-nil dt 25.08.2015 stating from the first marketing Submitted. (Pg No-35-39) NIT sl.no. 16,21 & 36 MSC not submitted. NIT sl. no 67, 105 & 143 pharmacopoeial specification is USP. NIT sl. no- 75 , 76 , 130 & 143 pack size specification not mentioned in the certificate.
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	Self attested copy of Non Conviction Certificate (NCC) issued by State Drug controller & Licensing Authority Baddi ,Solan, vide file no-HFW-H(DRUGS) 25/08 Vol-II dt 30.07.2015 submitted wherein it has been certified that the bidder firm neither been convicted by the Courts of Law in the State nor the Directorate has filed any prosecution against the bidder firm under the provsions of D & C Act, 1940 & Rules thereunder. (Pg No-30)
8	Self attested copies of WHO-GMP/GMP as per revised Schedule-'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year form the last date of submission of tender. As per clause 3(j).	Self attested copies of GMP Certificate as per revised Schedule- 'M' issued byState Drug controller & Licensing Authority Baddi ,Solan,vide file no-HFW-H(DRUGS) 25/08 Vol-II dt 01.08.2015. for Tablets, Capsules, Dry Syrups, Liquid Oral, Liquid and Dry Powder injections and sterile ophthalmic (General). Tablets, Capsules, Dry Syrups & Dry Powder Injections (Betalactam) and Liquid Injections (Hormonal). The certificate is valid for 02 yrs from the date of issue. (Pg- 31)
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section. As per Clause 3(k).	Self attested copies of Capacity Assesment Certificate (section wise) per shift issued by State Drug controller & Licensing Authority Baddi ,Solan,vide file no-HFW-H(DRUGS) 25/08 Vol-II dt 27.08.2015 submitted. Wherein Eye/Ear Drops - 1.60 Cr. , Liquid Inj. - 1.50 Cr. , Dry Inj. - 2.20 Cr. , Dry syrup- 90 Lac, Tablets- 60 Cr., Capsules 15 Cr. and Liquid Syrup- 1.00 Cr. mentioned. (Pg no-32)
10	An affidavit sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Copy of affidavit sworn before Notary by authorized person stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies or by BMSICL as per Annexure II submitted. (Pg. 27-29)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	Rs. 5 Lakhs, BG 1206151GFIN0015, Dena Bank
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	DD 891113 Rs. 10,000/- Dena Bank
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	F. Y. 14 - 15 Rs. 34.90 Cr. Pg. 25 F. Y. 13 - 14 Rs. 27.74 Pg. 24 F. Y. 12 - 13 Rs. 24.54 Cr. Pg. 23
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	A. J. 13 - 14 Pg. 16 A. J. 12 - 13 Pg. 19 A. J. 14 - 15 Pg. 13
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	AACFU0131E, Pg. 26.
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	02030100892, Pg. 6
17	Affidavit declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Copy of an affidavit sworn before Notary by authorized person on dt 25.08.2015 stating acceptance of tender conditions as per annexure IV. Submitted.(Pg-8-9)
The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due deligence and care, on the basis of document provided by BMSICL, in compliance of letter No 515(15) Dt-21.08.2015 of Health Department, Govt of Bihar and letter no BMSIC/40010/2-2014/1678 Dt 18.09.2015 of GM (Supply Chain), BMSICL, Patna. Inspite, some inadvertent dicrepancies could have been crept in. Humble request to all concerned to bring to notice in due time, if any discrepancies is observed, for rectification.		
	The facts in pages mentioned against the clause No-1 to 10 and 17 of this chart has been verified.	